Mounjaro, Zepbound see surge in popularity
Annual sales for Mounjaro and Zepbound, in U.S. dollars
Note: The U.S. Food and Drug Administration approved Mounjaro to treat Type 2 diabetes in 2022; Zepbound was approved for weight management in 2023.
Source: Eli Lilly and Co. annual reports, accessed through U.S. Securities and Exchange Commission’s EDGAR database.
Source: Eli Lilly and Co. annual reports, accessed through U.S. Securities and Exchange Commission’s EDGAR database.
PEW RESEARCH CENTER
Mounjaro, Zepbound see surge in popularity
Annual sales for Mounjaro and Zepbound, in U.S. dollars
| Year | Mounjaro | Zepbound | Total company revenue |
|---|---|---|---|
| 2022 | $482,500,000 | $0 | $28,541,400,000 |
| 2023 | $5,163,100,000 | $175,800,000 | $34,124,100,000 |
| 2024 | $11,540,100,000 | $4,925,700,000 | $45,042,700,000 |
Note: The U.S. Food and Drug Administration approved Mounjaro to treat Type 2 diabetes in 2022; Zepbound was approved for weight management in 2023.
Source: Eli Lilly and Co. annual reports, accessed through U.S. Securities and Exchange Commission’s EDGAR database.
Source: Eli Lilly and Co. annual reports, accessed through U.S. Securities and Exchange Commission’s EDGAR database.
PEW RESEARCH CENTER
